Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized GM-CSF in Recurrent Osteosarcoma
NCT00066365Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 2004
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label trial of sargramostim in osteosarcoma (OS) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Status of FAS Ligand in Pre/Post-chemotherapy Sample at 29 days, Presence of FAS in Pre/Post-chemotherapy Sample at 29 days and 5 more. Started Jul 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00066365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066365.